PMC Articles for PubChem Compound (Select 25141092) - PMC

Links from PubChem Compound

Items: 1 to 20 of 73

<< First< Prev

Page of 4

Select item 112714101.

Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial

Solange Peters, Shirish M. Gadgeel, Tony Mok, Ernest Nadal, Saadettin Kilickap, Aurélie Swalduz, Jacques Cadranel, Shunichi Sugawara, Chao-Hua Chiu, Chong-Jen Yu, Mor Moskovitz, Tomohiro Tanaka, Rhea Nersesian, Sarah M. Shagan, Margaret Maclennan, Michael Mathisen, Vijay Bhagawati-Prasad, Cheick Diarra, Zoe June Assaf, Venice Archer, Rafal Dziadziuszko

Nat Med. 2024; 30(7): 1923–1932. Published online 2024 Jun 19. doi: 10.1038/s41591-024-03008-4

PMCID:: PMC11271410

Abstract Article PDF–4.2M

Select item 112512942.

NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors

Eric Eunshik Kim, Chul-Kee Park, Seung-Ki Kim, Ji Hoon Phi, Sun Ha Paek, Jung Yoon Choi, Hyoung Jin Kang, Joo Ho Lee, Jae Kyung Won, Hongseok Yun, Sung-Hye Park

Acta Neuropathol Commun. 2024; 12: 118. Published online 2024 Jul 16. doi: 10.1186/s40478-024-01798-9

PMCID:: PMC11251294

Abstract Article PDF–2.5M

Select item 112178633.

Clinical characteristics and treatment patterns of patients with NTRK fusion–positive solid tumors: A multisite cohort study at US academic cancer centers

Connor Willis, Trang Au, Andre Hejazi, Cassia Griswold, Matthew B. Schabath, Jonathan Thompson, Jyoti Malhotra, Noah Federman, Gilbert Ko, Sreevalsa Appukkuttan, Neil Warnock, Sheldon X. Kong, Brian Hocum, Diana Brixner, David Stenehjem

J Manag Care Spec Pharm. 2024 Jul; 30(7): 672–683. doi: 10.18553/jmcp.2024.30.7.672

PMCID:: PMC11217863

Abstract Article PDF–314K

Select item 111946134.

Induction of resistance to neurotrophic tropomyosin‐receptor kinase inhibitors by HMGCS2 via a mevalonate pathway

Yasuhiro Kato, Masaru Matsumoto, Natsuki Takano, Mariko Hirao, Kuniko Matsuda, Takehiro Tozuka, Naomi Onda, Shinji Nakamichi, Susumu Takeuchi, Akihiko Miyanaga, Rintaro Noro, Akihiko Gemma, Masahiro Seike

Cancer Med. 2024 Jun; 13(12): e7393. Published online 2024 Jun 24. doi: 10.1002/cam4.7393

PMCID:: PMC11194613

Abstract Article PDF–5.1M

Select item 109107545.

CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles

Marc Terrones, Christophe Deben, Felicia Rodrigues-Fortes, Anne Schepers, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer

J Transl Med. 2024; 22: 234. Published online 2024 Mar 3. doi: 10.1186/s12967-024-04988-0

PMCID:: PMC10910754

Abstract Article PDF–5.1M

Select item 107723476.

Entrectinib inhibits NLRP3 inflammasome and inflammatory diseases by directly targeting NEK7

Xiangyu Jin, Didi Liu, Xinru Zhou, Xianyu Luo, Qian Huang, Yi Huang

Cell Rep Med. 2023 Dec 19; 4(12): 101310. Published online 2023 Dec 19. doi: 10.1016/j.xcrm.2023.101310

PMCID:: PMC10772347

Abstract Article PDF–5.1M

Select item 107498247.

Lung Injury Induced by Crizotinib and Entrectinib in a Patient with ROS1-rearranged Non-small-cell Lung Cancer

Yoshiki Nishiyama, Shota Omori, Hiroyuki Matsumoto, Kosaku Komiya, Kazufumi Hiramatsu

Intern Med. 2023 Dec 1; 62(23): 3507–3510. Published online 2023 Apr 14. doi: 10.2169/internalmedicine.1255-22

PMCID:: PMC10749824

Abstract Article PDF–616K

Select item 107351378.

Case report: Successful sequential therapy of crizotinb and entrectinib in ROS1-positive non-small-cell lung cancer with brain metastasis in later-settings

Wen Dong, Jinke Zhuge, Pengli Yu, Kai Liu, Mingxing Yang, Hongkang Wang

Medicine (Baltimore) 2023 Dec 22; 102(51): e36591. Published online 2023 Dec 22. doi: 10.1097/MD.0000000000036591

PMCID:: PMC10735137

Abstract Article PDF–823K

Select item 107130979.

Sequential treatments with TRK inhibitors in a patient with NTRK fusion-positive sarcoma: A case report

Yuta Kubota, Masanori Kawano, Tatsuya Iwasaki, Ichiro Itonaga, Hiroshi Tsumura, Nobuhiro Kaku, Kazuhiro Tanaka

Medicine (Baltimore) 2023 Dec 8; 102(49): e36232. Published online 2023 Dec 8. doi: 10.1097/MD.0000000000036232

PMCID:: PMC10713097

Abstract Article PDF–1.1M

Select item 1048114210.

Refractory response to entrectinib for ROS‐1 rearranged NSCLC with concurrent de novo TP53 mutation showing good response to CNS lesion, but poor duration of response: A case report

Kentaro Ito, Miho Nishio, Kentaro Fujiwara, Yoichi Nishii, Kengo Ushiro, Hiroki Yasui, Osamu Hataji

Thorac Cancer. 2023 Sep; 14(25): 2622–2626. Published online 2023 Aug 6. doi: 10.1111/1759-7714.15044

PMCID:: PMC10481142

Abstract Article PDF–1.4M

Select item 1048113511.

A case of CD74‐ROS1‐positive lung adenocarcinoma diagnosed by next‐generation sequencing achieved long‐term survival with pemetrexed regimens

Satoshi Tanaka, Nobuaki Yoshimura, Ryo Asakawa, Satoshi Tobita, Moto Yaga, Kiyonobu Ueno

Thorac Cancer. 2023 Sep; 14(25): 2618–2621. Published online 2023 Jul 24. doi: 10.1111/1759-7714.15041

PMCID:: PMC10481135

Abstract Article PDF–1018K

Select item 1039127112.

The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer

Joshua A. Roth, Josh J. Carlson, Fang Xia, Todd Williamson, Sean D. Sullivan

J Manag Care Spec Pharm. 2020 Aug; 26(8): 10.18553/jmcp.2020.20045. doi: 10.18553/jmcp.2020.20045

PMCID:: PMC10391271

Abstract Article PDF–198K

Select item 1039102213.

A RESPONSE TO “THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER”

Sarika Ogale, Clarissa Emy Higuchi Zerbini, Miranta Antoniou, Romain Freund

J Manag Care Spec Pharm. 2020 Dec; 26(12): 10.18553/jmcp.2020.26.12.1616. doi: 10.18553/jmcp.2020.26.12.1616

PMCID:: PMC10391022

Article PDF–111K

Select item 1004623414.

Tyrosine Kinase Inhibitors Target B Lymphocytes

Nikki Lyn Esnardo Upfold, Pavlo Petakh, Aleksandr Kamyshnyi, Valentyn Oksenych

Biomolecules. 2023 Mar; 13(3): 438. Published online 2023 Feb 25. doi: 10.3390/biom13030438

PMCID:: PMC10046234

Abstract Article PDF–1.2M

Select item 1003347315.

Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations

Georgina Meneses-Lorente, Elena Guerini, Francois Mercier, Neil Parrott, Karey Kowalski, Edna Chow-Maneval, Vincent Buchheit, Guillaume Bergthold, Elizabeth Fox, Alex Phipps, Nassim Djebli

Cancer Chemother Pharmacol. 2023; 91(3): 239–246. Published online 2023 Mar 8. doi: 10.1007/s00280-023-04510-1

PMCID:: PMC10033473

Abstract Article PDF–1.1M

Select item 1002802416.

MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements

Yohei Takumi, Sachiko Arai, Chiaki Suzuki, Koji Fukuda, Akihiro Nishiyama, Shinji Takeuchi, Hiroki Sato, Kunio Matsumoto, Kenji Sugio, Seiji Yano

Cancer Med. 2023 Mar; 12(5): 5809–5820. Published online 2022 Nov 23. doi: 10.1002/cam4.5342

PMCID:: PMC10028024

Abstract Article PDF–2.9M

Select item 987495817.

Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer: a case report

Inês Damásio, Joana Simões-Pereira, Sara Donato, Mariana Horta, Branca Maria Cavaco, Miguel Rito, Pedro Gomes, Valeriano Leite

Eur Thyroid J. 2023 Feb 1; 12(1): e220179. Published online 2022 Dec 22. doi: 10.1530/ETJ-22-0179

PMCID:: PMC9874958

Abstract Article PDF–1.2M

Select item 962630718.

MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC

Logan C. Tyler, Anh T. Le, Nan Chen, Hala Nijmeh, Liming Bao, Timothy R. Wilson, David Chen, Brian Simmons, Kristen M. Turner, Dean Perusse, Shailaja Kasibhatla, Jason Christiansen, Arkadiusz Z. Dudek, Robert C. Doebele

Thorac Cancer. 2022 Nov; 13(21): 3032–3041. Published online 2022 Sep 13. doi: 10.1111/1759-7714.14656

PMCID:: PMC9626307

Abstract Article PDF–1.8M

Select item 952751819.

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)

Ami V Desai, Giles W Robinson, Karen Gauvain, Ellen M Basu, Margaret E Macy, Luke Maese, Nicholas S Whipple, Amit J Sabnis, Jennifer H Foster, Suzanne Shusterman, Janet Yoon, Brian D Weiss, Mohamed S Abdelbaki, Amy E Armstrong, Thomas Cash, Christine A Pratilas, Nadège Corradini, Lynley V Marshall, Mufiza Farid-Kapadia, Saibah Chohan, Clare Devlin, Georgina Meneses-Lorente, Alison Cardenas, Katherine E Hutchinson, Guillaume Bergthold, Hubert Caron, Edna Chow Maneval, Amar Gajjar, Elizabeth Fox

Neuro Oncol. 2022 Oct; 24(10): 1776–1789. Published online 2022 Apr 8. doi: 10.1093/neuonc/noac087

PMCID:: PMC9527518

Abstract Article PDF–7.3M

Select item 950359120.

Doxorubicin-Induced TrkAIII Activation: A Selection Mechanism for Resistant Dormant Neuroblastoma Cells

Lucia Cappabianca, Michela Sebastiano, Marianna Ruggieri, Maddalena Sbaffone, Veronica Zelli, Antonietta Rosella Farina, Andrew Reay Mackay

Int J Mol Sci. 2022 Sep; 23(18): 10895. Published online 2022 Sep 17. doi: 10.3390/ijms231810895

PMCID:: PMC9503591

Abstract Article PDF–9.4M

PMC

Result Filters

Article attributes

Text availability

Publication date

Custom date range

Research Funder

Additional filters

Display Settings:

Send to:

Links from PubChem Compound

Items: 1 to 20 of 73

Display Settings:

Send to:

Supplemental Content

Find related data

Recent activity